Drug Search Results
More Filters [+]

Topiroxostat

Alternative Names: topiroxostat
Latest Update: 2023-05-05
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: XO Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: India | Japan

Approved Indications: None

Known Adverse Events: None

Company: Fuji Yakuhin
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Topiroxostat

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Gout

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20202265

P1

Recruiting

Gout

None

Recent News Events